US prepares for imminent Centers for Medicare & Medicaid Services outpatient, ambulatory reimbursement
This article was originally published in Clinica
When US Medicare proposed sweeping changes in how it calculates diagnosis-related groups (DRGs) under its inpatient payment system earlier this year, it prompted a policy uproar. Analysts weighed in with estimates of earnings losses, while the device industry formed coalitions, commissioned studies, held high-profile press conferences and advertised in key newspapers. Ultimately, the strategy worked. The health plan's proposed payment strategies for both outpatient and ambulatory surgical centres have been treated with far less fanfare.
You may also be interested in...
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.